FDA Updates List of Drugs for Compounding

Dexamethasone Sodium Phosphate Added to the List of Drugs for Temporary Compounding

by | Jul 15, 2020 | All Posts, COVID-19, FDA

The FDA has added Dexamethasone Sodium Phosphate to the list of drugs for temporary compounding by outsourcing facilities and pharmacy compounders during the COVID-19 pandemic. This update helps address shortages and access concerns affecting some drugs urgently needed for hospitalized COVID-19 patients.

Thank you for reading this post, don't forget to subscribe!

The updated lists are referenced in the following guidances:

The FDA states that hospitals that can’t obtain adequate supplies of FDA-approved drugs and are considering the use of compounded drugs for their hospitalized patients should first contact outsourcing facilities.

The List of Drugs Which This Guidance Applies To:

Products that are aqueous solutions for injection:

  1. Cisatracurium besylate
  2. Dexmedetomidine hydrochloride
  3. Dexamethasone sodium phosphate
  4. Etomidate
  5. Fentanyl citrate
  6. Furosemide
  7. Hydromorphone hydrochloride
  8. Ketamine hydrochloride
  9. Lorazepam
  10. Midazolam hydrochloride
  11. Norepinephrine bitartrate
  12. Rocuronium bromide
  13. Vancomycin hydrochloride
  14. Vecuronium bromide

Who We Are

Eagle consultants and scientists are helping compounding facilities implement successful quality systems. Our team has over 200 years of combined experience in the FDA-regulated pharmaceutical industry and can provide guidance in establishing the systems and processes that will help facilities producing compounded medications meet and exceed regulatory expectations. Follow the link below to learn more about our consulting services.

Eagle Analytical
Verified by MonsterInsights